02:02 , Jan 14, 2017 |  BioCentury  |  Strategy

Solidifying Takeda’s position

Takeda Pharmaceutical Co. Ltd. ’s proposed acquisition of Ariad Pharmaceuticals Inc. should be the boost the pharma needs to hit $10 billion in cancer sales by 2025, as the biotech’s brigatinib is expected to lead...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Company News

Amgen, Takeda deal

Takeda said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG 386 ) to Amgen. In 2008, Amgen granted exclusive, Japanese rights to Takeda for up to 13 compounds,...
00:22 , Jun 25, 2016 |  BC Extra  |  Company News

Takeda ends Japan deal for two Amgen candidates

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said it returned its Japanese rights to fulranumab ( AMG 403 ) and trebananib ( AMG 386 ) to Amgen Inc. (NASDAQ:AMGN). In April, Johnson & Johnson (NYSE:JNJ) said it...
08:00 , Nov 10, 2014 |  BC Week In Review  |  Clinical News

Trebananib: Additional Phase III data

Additional data from the double-blind, international Phase III TRINOVA-1 trial in over 900 women with recurrent partially platinum-sensitive or platinum-resistant ovarian cancer, primary peritoneal cancer or fallopian tube cancer showed that once-weekly 15 mg/kg IV...
02:46 , Nov 5, 2014 |  BC Extra  |  Clinical News

Amgen's trebananib misses Phase III OS endpoint

Amgen Inc. (NASDAQ:AMGN) reported that trebananib failed to improve overall survival among recurrent platinum-resistant ovarian cancer patients in the Phase III TRINOVA-1 study. The compound missed the top-line secondary endpoint of statistically significant improvement of...
07:00 , Oct 27, 2014 |  BioCentury  |  Strategy

Amgen on notice

Amgen Inc. left itself open to the shot fired by activist investor Third Point LLC by failing to apply the ruthless discipline to pipeline pruning that other large companies have undertaken under new management regimes....
08:00 , Feb 3, 2014 |  BioCentury  |  Product Development

Spies graduate

The initial results from I-SPY 2 are a fine rebuttal to industry skeptics who doubted the academic groups in charge had the ability to quickly run a robust clinical trial across multiple tumor types. In...
08:00 , Jan 27, 2014 |  BC Week In Review  |  Clinical News

Trebananib regulatory update

The European Commission granted Orphan Drug designation to Amgen's trebananib to treat ovarian cancer. The recombinant Fc-peptide fusion protein (peptibody) targeting angiopoietins is in Phase III testing for the indication. Takeda has exclusive Japanese rights...
08:00 , Dec 16, 2013 |  BC Week In Review  |  Clinical News

Veliparib: Phase II data

Researchers at the University of California , San Francisco and colleagues said a veliparib-containing regimen "graduated" from the open-label Phase II I-SPY 2 trial based on having a high probability of success in patients with...
08:00 , Dec 9, 2013 |  BC Week In Review  |  Clinical News

Oral neratinib: Phase II data

Puma said a neratinib-containing regimen "graduated" from the open-label I-SPY 2 trial based on having a high probability of success in patients with HER2-positive/hormone receptor-negative breast cancer in a Phase III trial. The company said...